<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130817</url>
  </required_header>
  <id_info>
    <org_study_id>Should be 2013-0672</org_study_id>
    <secondary_id>IM103-327</secondary_id>
    <nct_id>NCT02130817</nct_id>
  </id_info>
  <brief_title>Belatacept in Kidney Transplantation of Moderately Sensitized Patients</brief_title>
  <acronym>BelatPilot</acronym>
  <official_title>Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive
      medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a
      standard of care regimen of immunosuppressive medications and plasma exchange (plasmapheresis
      and immunoglobulin treatment) for kidney transplant patients who are moderately sensitized
      against their deceased donor and at-risk for delayed graft function. The hypothesis is that
      moderately sensitized patients who receive Belatacept treatment with the standard of care
      regimen will lead to lower acute rejection rates than historical controls based on assessment
      of standard of care biopsies and standard Banff criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory single-center, open-label safety and efficacy study will enroll 20 adult
      kidney transplants candidates, moderately sensitized against their deceased donor and at-risk
      for delayed graft function (DGF), to receive Belatacept (days 0,5, weeks 2,4,8 and 12 (10
      mg/kg), and every 4 weeks thereafter (5 mg/kg)), plasma exchange (once before and twice after
      transplant) and Intravenous Immunoglobulin (IVIG) (100 mg/kg after each plasma exchange),
      along with Thymoglobulin (ATG) induction and Dexamethasone tapered dosing starting on the day
      of transplant at 100mg IV, tapered through Day 4, followed by prednisone at 30 mg on Day 5
      with tapered dosing to prednisone 10 mg/d by one month, with a total observation period of 1
      year. Patients will be tapered off tacrolimus by week 8 and will remain on mycophenolic acid
      and prednisone for the total length of the study. Subjects will be followed until 1 year post
      transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>one year</time_frame>
    <description>Acute rejection rates are based on assessment of standard of care biopsy (protocol and indication) and standard Banff criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and Graft Survival</measure>
    <time_frame>One year</time_frame>
    <description>The number of subjects alive and with functioning grafts at one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>One year</time_frame>
    <description>Number of subjects in the study who have developed infections, including cytomegalovirus (CMV) and BK Virus, in the first year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of de novo donor specific antibody (DSA)</measure>
    <time_frame>One year</time_frame>
    <description>Number of subjects who have developed donor specific antibodies at one year post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new onset diabetes</measure>
    <time_frame>One year</time_frame>
    <description>Number of subjects in the study who have developed new onset diabetes since receiving the transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>One year</time_frame>
    <description>Number of subjects in the study whose eGFR has decreased to &lt; 45 milliliters/ minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of malignancies</measure>
    <time_frame>One year</time_frame>
    <description>Number of subjects in the study who have developed malignancies including post-transplant lymphoproliferative (PTLD) disorder</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Antibody Mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept (nujolix):
Tacrolimus withdrawal
Standard of care(SOC) treatment:
Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy
Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.
Maintenance immunosuppression:
Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>Nujolix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus withdrawal</intervention_name>
    <description>Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.</description>
    <arm_group_label>Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasmapheresis/Intravenous Immunoglobulin G</intervention_name>
    <description>Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.</description>
    <arm_group_label>Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin (ATG)</intervention_name>
    <description>Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>Anti-thymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.</description>
    <arm_group_label>Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>Dexamethasone, Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 18-70 years of age

          -  Patient who is receiving an expanded criteria donor (ECD) or deceased cardiac donor
             (DCD) kidney

          -  Have immunodominant donor specific antibodies (DSA) 1,000 - 4,000 mean fluorescent
             intensity (MFI) by single bead Luminex bioassay

          -  Subjects must be capable of understanding the investigational nature and risks of the
             study and must sign a statement of informed consent

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within the past 48 hours prior to study inclusion and be willing to use
             contraceptives for the duration of the study and for 8 weeks after the last dose of
             study drug Women of Child-Bearing Potential (WOCBP) includes

          -  Women who have experienced menarche and who have not undergone successful surgical
             sterilization or who are not post-menopausal

          -  Women using oral contraceptives, other hormonal contraceptives, or mechanical products
             such as intrauterine devices or barrier methods

          -  Women who are practicing abstinence

          -  Women who have a partner who is sterile (eg, due to vasectomy).

          -  Women must not be breast-feeding

          -  Male subjects must agree to use an acceptable method for contraception for the
             duration of the study

          -  Patient must have known positive Epstein-Barr virus (EBV) serostatus

        Exclusion Criteria:

          -  Patient has previously received an organ transplant other than a kidney.

          -  Patient is receiving an human leukocyte antigen (HLA) identical living donor
             transplant

          -  Patient who is a recipient of a multiple organ transplant

          -  Patient with a positive T or B cell crossmatch

          -  Patient with a donor specific antibody (DSA) as deemed by the local PI to be
             associated with significant risk of rejection

          -  Patient has received an ABO incompatible donor kidney

          -  Recipients will be receiving a dual or en bloc kidney transplant

          -  Donor anticipated cold ischemia is &gt; 30hours

          -  Recipient or donor is known to be seropositive for hepatitis C virus (HCV) or B virus
             (HBV) except for hepatitis B surface antibody positive. HCV seropositive patients with
             a negative HCV viral load testing may be included.

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)

          -  Seronegative or unknown EBV serostatus

          -  Patient has uncontrolled concomitant infection or any other unstable medical condition
             that could interfere with the study objectives

          -  Patients with tuberculosis who have not been treated for latent infection.

          -  Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to
             BK virus infection

          -  Patients at high risk for polyoma virus-associated nephropathy, which is mostly due to
             BK virus infection

          -  Patients with thrombocytopenia (PLT &lt;75,000/mm3), and/or leucopoenia (WBC &lt;
             2,000/mm3), or anemia (hemoglobin &lt; 6 g/dL) prior to study inclusion.

          -  Patient is taking or has been taking an investigational drug in the 30 days prior to
             transplant

          -  Patient who has undergone desensitization therapy within 6 months prior to transplant

          -  Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil,
             alemtuzumab, rabbit anti-thymocyte globulin, or glucocorticoids

          -  Patient is receiving chronic steroid therapy at the time of transplant

          -  Patients with a history of cancer (other than non-melanoma skin cell cancers cured by
             local resection) within the last 5 years

          -  Patients with &gt; Grade 2 peripheral neuropathy within 14 days before enrollment

          -  Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiography evidence of acute
             ischemia or active conduction system abnormalities.

          -  Female subject is pregnant or breast-feeding

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study. Subjects who are compulsorily detained for treatment of either a
             psychiatric or physical illness

          -  Prisoners or subjects who are involuntarily incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjang Djamali, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arjang Djamali, M.D.</last_name>
    <phone>608-262-9306</phone>
    <email>axd@medicine.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Jacobson, M.S.</last_name>
    <phone>608-263-3369</phone>
    <email>lmj@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wiscsonsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjang Djamali, M.D.</last_name>
      <phone>608-262-9306</phone>
      <email>axd@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Jacobson, M.S.</last_name>
      <phone>608-263-3369</phone>
      <email>lmj@medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arjang Djamali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009 May 27;87(10):1555-61. doi: 10.1097/TP.0b013e3181a4b91b.</citation>
    <PMID>19461494</PMID>
  </reference>
  <reference>
    <citation>Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol. 2006 May;1(3):421-32. Epub 2006 Apr 12. Review.</citation>
    <PMID>17699241</PMID>
  </reference>
  <reference>
    <citation>Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006 Feb;6(2):346-51.</citation>
    <PMID>16426319</PMID>
  </reference>
  <reference>
    <citation>Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17;359(3):242-51. doi: 10.1056/NEJMoa0707894.</citation>
    <PMID>18635429</PMID>
  </reference>
  <reference>
    <citation>Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant. 2004 Dec;8(6):535-42.</citation>
    <PMID>15598320</PMID>
  </reference>
  <reference>
    <citation>Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation. 2008 Jul 15;86(1):96-103. doi: 10.1097/TP.0b013e318176ae2c.</citation>
    <PMID>18622284</PMID>
  </reference>
  <reference>
    <citation>Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009 Jan 27;87(2):268-73. doi: 10.1097/TP.0b013e3181919a16.</citation>
    <PMID>19155983</PMID>
  </reference>
  <reference>
    <citation>Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009 Jul 15;88(1):1-6. doi: 10.1097/TP.0b013e3181a9e89a. Review.</citation>
    <PMID>19584672</PMID>
  </reference>
  <reference>
    <citation>Investigator Brochure. Belatacept (BMS-2224818), Version 13. Bristol-Myers Squibb Research and Development Department. 15 December 2010.</citation>
  </reference>
  <reference>
    <citation>U.S. Prescribing information for NulojixÂ® (belatacept), Revised 06/2011. Bristol-Myers Squibb.</citation>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2014</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Transplant</keyword>
  <keyword>Kidney Transplant</keyword>
  <keyword>Mean flourescent Intensity</keyword>
  <keyword>Delayed Graft Function</keyword>
  <keyword>Antagonist of Thymocyte Cell Activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

